The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

They also considered issues affecting the future use of PPV23 and pneumococcal conjugate vaccines in the elderly and adults at high risk of pneumococcal disease. PPV23 covers 80–90% of the ...

Lowering the age for the shot gives more adults the opportunity to protect themselves from pneumococcal disease at the age when risk of infection substantially increases, the agency said.

A study evaluated a pneumococcal vaccine containing 8 (types 1, 3, 6, 7, 14, 18, 19, and 23) capsular polysaccharides in children and young adults aged 2 to 25 years with sickle cell disease ...

Methods A nationally representative sample of US adults (aged ≥18 years ... health conditions and influenza and pneumococcal vaccination status. Data were analysed in 2022. Results Among 577 909 ...